Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
New evidence suggests that low levels of trans fatty acids (TFAs) may not be as harmful to human health as previously thought, even if industrially produced, and may even be beneficial if they occur naturally in foods such as dairy and meat products, according to a study published today (Wednesday) in the European Heart Journal .
Sophia Antipolis, 23 September 2015. Artificial TFAs occur when oil goes through a process of hydrogenation, which makes the oil more solid. They are used as ingredients in processed foods, such as cakes, biscuits and pies, and for frying. It has been well-established that high levels of industrially produced TFAs in food can lead to high cholesterol, heart problems, strokes and diabetes, and they have even been linked to infertility, Alzheimer’s disease and some cancers. Action has been taken in the USA to reduce the amount of artificially produced TFAs in food, while intake of these has tended to be lower in most of Europe. However, until now it has been unclear what is the highest concentration of TFAs that is safe for humans, and whether or not there is any difference between industrially produced TFAs and naturally occurring ones.Researchers in Germany, led by Dr Marcus Kleber, a post-doctoral researcher at the Vth Department of Medicine of the Medical Faculty Mannheim at Heidelberg University, measured the concentrations of TFAs found in the membranes of red blood cells in participants in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. A total of 3316 people living in south-western Germany joined the study between 1997 and 2000 after being hospitalised in order to have coronary angiographies to investigate heart disease, and 3,259 of them were analysed for this study. During a median follow-up period of just over 10 years (ranging from less than one year to nearly 12 years), 975 (30%) of these patients died.The researchers analysed blood samples from the patients to identify the total concentrations of TFAs, as well as distinguishing between the concentrations of industrially produced and naturally occurring TFAs. They linked this with information on deaths, causes of death, medical history, and other factors that could affect results, such as whether or not the patient were taking cholesterol-lowering drugs, such as statins, and risk factors such as smoking, lack of physical exercise, body mass index (BMI), diabetes and high blood pressure.Dr Kleber said: “We found that higher concentrations of TFAs in the membranes of red blood cells were associated with higher LDL or ‘bad’ cholesterol, but also with lower BMI, lower fats in the blood (triglycerides) and less insulin resistance and, therefore, a lower risk of diabetes. We were surprised to find that naturally occurring TFAs were associated with a lower rate of deaths from any cause, and this was driven mainly by a lower risk of sudden cardiac death. “We were also surprised to see that increases in the concentrations of industrially produced TFAs were not followed by increased mortality, which stands in contrast to observations from the United States. The reason for this may be, that in our group of German patients, TFAs were in general much lower than those found in the United States, so that hardly anybody in the study reached concentrations common to people in the US.”The proportion of TFAs in the blood of the study participants ranged from 0.27-2.40% of total fatty acids, with an average of just under one percent. Another study in the USA over a similar time period reported an average of more than 2.6% of total fatty acids.The patients were divided into three groups: those that had the highest concentrations of naturally occurring TFAs (greater than 0.2%) had a 37% reduced risk of sudden cardiac death as compared to those with the lowest concentration, after adjusting for various factors that could affect the results. Results for any other associations between total TFAs, industrially produced TFAs or naturally occurring TFAs and death were mostly not statistically significant after adjustments for confounding factors. Dr Kleber said: “Our results show that the low levels of industrially produced TFA we found in the LURIC study did not pose a health risk, and therefore could be regarded as safe. We also found that trans-palmitoleic acid (a naturally occurring TFA found in milk and meat from ruminant animals) is associated with better blood glucose levels and fewer deaths from any cause, but especially a lower risk of sudden cardiac death.“According to previous research , TFA consumption in European countries varies considerably. Mediterranean countries traditionally use more olive oil than hydrogenated vegetable oils and therefore their diet contains less TFA than the traditional diet in northern European countries. However, TFA consumption in some eastern European countries and in some developing countries remains high. Unfortunately, focusing on intake has important limitations that can be circumvented by focusing on red blood cell levels, as we did in our study. Therefore, our data support a new approach to investigating TFAs and provide evidence that naturally occurring TFAs have to be differentiated from industrially produced TFAs.”He said LURIC, led by Professor Winfried März, was an important epidemiological study due to the long follow-up period of observation and the detailed information on the participants. “Our findings were made possible by combining LURIC with analysing levels of fatty acids in red blood cells with a specific method established in Professor Clemens von Schacky's laboratory, which reduces both the day-to-day variability of the sample as well as the variability in the measurement. We feel that we will be able to say more about fatty acids and their importance for health in the future.”(ends)
Notes: “Trans Fatty Acids and Mortality in Patients referred for Coronary Angiography - The Ludwigshafen Risk and Cardiovascular Health Study”, by Marcus E. Kleber, Graciela E Delgado, Stefan Lorkowski, Winfried März, and Clemens von Schacky. European Heart Journal. doi:10.1093/eurheartj/ehv446 Craig-Schmidt MC. World-wide consumption of trans fatty acids. Atheroscler Suppl. 2006;7(2):1-4.andHulshof KF, van Erp-Baart MA, Anttolainen M, Becker W, Church SM, Couet C, et al. Intake of fatty acids in western Europe with emphasis on trans fatty acids: the TRANSFAIR Study. Eur J Clin Nutr. 1999;53(2):143-57.The European Heart Journal is the flagship journal of the European Society of Cardiology http://www.escardio.org). It is published on behalf of the ESC by Oxford Journals, a division of Oxford University Press. Please acknowledge the journal as a source in any articles.
ESC Press OfficeTel: +33 (0) 4 92 94 86 27 Email: email@example.com
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.
© 2017 European Society of Cardiology. All rights reserved